Colon, Phase III
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Volunteers
Health Professionals
What is the purpose of this trial?
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alison Johnson
- Anca Bulgaru, MD
- Andrea Brennan
- Armand Russo, MD
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- Clarice Grens
- D. Barry Boyd, MD, MS
- Elan Gorshein, DO, JD, MPH
- Emily Kopas, APRN, OCN
- Jacquelyne Gaddy, MD, MSc, MSCR
- James Vredenburgh, MD
- Jason Haldas, MD
- Jill Lacy, MD
- Johanna LaSala, MD
- Jose Morales-Marin
- Justin Persico, MD
- Katelyn Scott
- Kayla Martello
- Kristen Hoxie
- Larisa Fleysher
- Laura Sabourin
- Laura Van Metre Baum, MD, MPH
- M. Sung Lee, MD
- Madeline Santiago
- Matthew Austin, MD
- Michael Burke
- Michael Cecchini, MD
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Osarugue Otasowie
- Pamela L. Kunz, MD
- Pawan Karanam, MD
- Renee Moye
- Robert Legare, MD
- Sara Anastasio, RN
- Sarah Carlson
- Stacey Stein, MD
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Teresa White
- Thejal Srikumar, MD, MPH
- Vanna Dest
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Yifei Zhang, MD
- Zia Rahman, MD
- Last Updated11/14/2024
- Study HIC#2000037423